Xenetic Biosciences Inc XBIO
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if XBIO is a good fit for your portfolio.
News
Trading Information
- Previous Close Price
- $3.85
- Day Range
- $3.75–3.98
- 52-Week Range
- $2.55–5.97
- Bid/Ask
- $3.75 / $3.95
- Market Cap
- $5.82 Mil
- Volume/Avg
- 1,657 / 5,803
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 2.32
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Xenetic Biosciences Inc is a biopharmaceutical company focused on advancing immune-oncology technologies addressing cancers. The company is also engaged in progressing XCART, a personalized CAR T platform technology. The Company's DNase platform is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which have been implicated in cancer progression and resistance to cancer treatments. The company also has oncology therapeutic investigational drug candidate XBIO-101 for the treatment of progestin-resistant endometrial cancer.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 4
- Website
- https://www.xeneticbio.com
Valuation
|
Metric
|
XBIO
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 0.61 |
Price/Sales | 2.32 |
Price/Cash Flow | — |
Price/Earnings
XBIO
Financial Strength
|
Metric
|
XBIO
|
|---|---|
Quick Ratio | 11.10 |
Current Ratio | 11.84 |
Interest Coverage | — |
Quick Ratio
XBIO
Profitability
|
Metric
|
XBIO
|
|---|---|
Return on Assets (Normalized) | −30.21% |
Return on Equity (Normalized) | −32.61% |
Return on Invested Capital (Normalized) | −35.61% |
Return on Assets
XBIO
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Fvjbcmqkls | Mjb | $562.4 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Qnqjyhmp | Wfqvhpx | $103.6 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Bggqtsqs | Vrbfb | $99.5 Bil | |
MRNA
| Moderna Inc | Rjqrdyp | Ttsx | $38.8 Bil | |
ARGX
| argenx SE ADR | Ffgmkwcjb | Rkzz | $22.3 Bil | |
BNTX
| BioNTech SE ADR | Csxkfhvr | Xcz | $21.2 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Jsqqjmxp | Gfcvhn | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Wqtmbgwtg | Yxwyks | $17.3 Bil | |
RPRX
| Royalty Pharma PLC Class A | Wzyymdqvj | Cdxmhp | $12.5 Bil | |
INCY
| Incyte Corp | Nghypmhb | Hphft | $11.6 Bil |